{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,24]],"date-time":"2026-01-24T17:42:38Z","timestamp":1769276558185,"version":"3.49.0"},"reference-count":35,"publisher":"Japanese Society for Lymphoreticular Tissue Research","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCEH","J Clin Exp Hematopathol"],"published-print":{"date-parts":[[2023,12,26]]},"DOI":"10.3960\/jslrt.23032","type":"journal-article","created":{"date-parts":[[2023,12,25]],"date-time":"2023-12-25T22:12:24Z","timestamp":1703542344000},"page":"219-229","source":"Crossref","is-referenced-by-count":3,"title":["Treatment patterns in patients with chronic lymphocytic                    leukemia\/small lymphocytic lymphoma post covalent Bruton tyrosine kinase                    inhibitor treatment: a Japanese claims database study"],"prefix":"10.3960","volume":"63","author":[{"given":"Dai","family":"Maruyama","sequence":"first","affiliation":[{"name":"Department of Hematology Oncology, Cancer Institute Hospital,                            Japanese Foundation for Cancer Research, Tokyo, Japan,"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chaochen","family":"Wang","sequence":"additional","affiliation":[{"name":"Eli Lilly Japan K.K, Kobe, Japan,"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshinori","family":"Tanizawa","sequence":"additional","affiliation":[{"name":"Eli Lilly Japan K.K, Kobe, Japan,"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhihong","family":"Cai","sequence":"additional","affiliation":[{"name":"Eli Lilly Japan K.K, Kobe, Japan,"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yujing","family":"Huang","sequence":"additional","affiliation":[{"name":"Eli Lilly and Company, Indianapolis, USA,"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masaomi","family":"Tajimi","sequence":"additional","affiliation":[{"name":"Eli Lilly Japan K.K, Kobe, Japan,"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shigeru","family":"Kusumoto","sequence":"additional","affiliation":[{"name":"Department of Hematology and Oncology, Nagoya City University                            Graduate School of Medical Sciences, Nagoya, Japan,"},{"name":"Department of Hematology and Cell Therapy, Aichi Cancer Center                            Hospital, Nagoya, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"2349","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1 Zhang                            S,                                Kipps                            TJ. The                    pathogenesis of chronic lymphocytic leukemia. Annu Rev Pathol. 2014; 9:                    103-118.","DOI":"10.1146\/annurev-pathol-020712-163955"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2 Swerdlow                            SH,                                Campo                            E,                                Pileri                            SA                    <i>et al.<\/i> The 2016 revision of the World Health Organization                    classification of lymphoid neoplasms. Blood. 2016; 127:                    2375-2390.","DOI":"10.1182\/blood-2016-01-643569"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3 Chihara                            D,                                Ito                            H,                                Matsuda                            T                    <i>et al.<\/i> Differences in incidence and trends of haematological                    malignancies in Japan and the United States. Br J Haematol. 2014; 164:                    536-545.","DOI":"10.1111\/bjh.12659"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4 Omi                            A,                                Nomura                            F,                                Tsujioka                            S,                                Fujino                            A,                                Akizuki                            R. Efficacy and                    safety of ibrutinib in relapsed\/refractory CLL and SLL in Japan: a                    post-marketing surveillance. J Clin Exp Hematop. 2022; 62:                    136-146.","DOI":"10.3960\/jslrt.22002"},{"key":"5","unstructured":"5 Japanese Society of Hematology. JSH                    practical guidelines for hematological malignancies. Chapter I Leukemia. I                    Leukimia. 5 Chronic lymphocyite leukemia\/small lymocytic lymphoma                    (CLL\/SLL)2018."},{"key":"6","doi-asserted-by":"crossref","unstructured":"6 Hallek                            M,                                Cheson                            BD,                                Catovsky                            D                    <i>et al.<\/i> iwCLL guidelines for diagnosis, indications for                    treatment, response assessment, and supportive management of CLL. Blood. 2018;                    131: 2745-2760.","DOI":"10.1182\/blood-2017-09-806398"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7 Bewarder                            M,                                Stilgenbauer                            S,                                Thurner                            L,                                Kaddu-Mulindwa                            D. Current                    Treatment Options in CLL. Cancers (Basel). 2021; 13: 2468.","DOI":"10.3390\/cancers13102468"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8 Roeker                            LE,                                Dreger                            P,                                Brown                            JR                    <i>et al.<\/i> Allogeneic stem cell transplantation for chronic                    lymphocytic leukemia in the era of novel agents. Blood Adv. 2020; 4:                    3977-3989.","DOI":"10.1182\/bloodadvances.2020001956"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9 Shanafelt                            TD,                                Wang                            XV,                                Kay                            NE                    <i>et al.<\/i> Ibrutinib-Rituximab or Chemoimmunotherapy for Chronic                    Lymphocytic Leukemia. N Engl J Med. 2019; 381: 432-443.","DOI":"10.1056\/NEJMoa1817073"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10 Sharman                            JP,                                Egyed                            M,                                Jurczak                            W                    <i>et al.<\/i> Acalabrutinib with or without obinutuzumab versus                    chlorambucil and obinutuzumab for treatment-naive chronic lymphocytic leukaemia                    (ELEVATE-TN): a randomised, controlled, phase 3 trial. Lancet. 2020; 395:                    1278-1291.","DOI":"10.1016\/S0140-6736(20)30262-2"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11 Shanafelt                            TD,                                Wang                            XV,                                Hanson                            CA                    <i>et al.<\/i> Long-term outcomes for ibrutinib-rituximab and                    chemoimmunotherapy in CLL: updated results of the E1912 trial. Blood. 2022; 140:                    112-120.","DOI":"10.1182\/blood.2021014960"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12 Sharman                            JP,                                Egyed                            M,                                Jurczak                            W                    <i>et al.<\/i> Efficacy and safety in a 4-year follow-up of the                    ELEVATE-TN study comparing acalabrutinib with or without obinutuzumab versus                    obinutuzumab plus chlorambucil in treatment-na\u00efve chronic lymphocytic leukemia.                    Leukemia. 2022; 36: 1171-1175.","DOI":"10.1038\/s41375-021-01485-x"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13 Woyach                            JA. Management                    of relapsed\/refractory Chronic Lymphocytic Leukemia. Am J Hematol. 2022; 97:                    S11-S18.","DOI":"10.1002\/ajh.26683"},{"key":"14","unstructured":"14 CANCER STATISTICS IN JAPAN \u2014 2023. Available                    on                    https:\/\/ganjoho.jp\/public\/qa_links\/report\/statistics\/pdf\/cancer_statistics_2023.pdf.                    Accessed on 22 September 2023."},{"key":"15","unstructured":"15 Charlson Comorbidity Index. Imporving Patient                    Outcomes. Available on http:\/\/www.charlsoncomorbidity.com\/. Accessed on 18 May                    2023."},{"key":"16","unstructured":"16 Barthel Index of Activities of Daily Living.                    Available on                    https:\/\/www.bgs.org.uk\/sites\/default\/files\/content\/attachment\/2018-07-05\/barthel.pdf.                    Accessed on 18 May 2023."},{"key":"17","doi-asserted-by":"crossref","unstructured":"17 Ou                            Y,                                Long                            Y,                                Ji                            L                    <i>et al.<\/i> Trends in Disease Burden of Chronic Lymphocytic Leukemia                    at the Global, Regional, and National Levels From 1990 to 2019, and Projections                    Until 2030: A Population-Based Epidemiologic Study. Front Oncol. 2022; 12:                        840616.","DOI":"10.3389\/fonc.2022.840616"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18 Takizawa                            J,                                Izutsu                            K,                                Nagai                            H                    <i>et al.<\/i> Real World Treatment Practices for Chronic Lymphocytic                    Leukemia in Japan: An Observational Database Research Study (CLIMBER-DBR). J                    Clin Exp Hematop. 2021; 61: 126-134.","DOI":"10.3960\/jslrt.20044"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19 Goede                            V,                                Cramer                            P,                                Busch                            R                    <i>et al.<\/i> Interactions between comorbidity and treatment of                    chronic lymphocytic leukemia: results of German Chronic Lymphocytic Leukemia                    Study Group trials. Haematologica. 2014; 99: 1095-1100.","DOI":"10.3324\/haematol.2013.096792"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20 Huang                            SJ,                                Gerrie                            AS,                                Young                            S                    <i>et al.<\/i> Impact of age and treatment institution type on outcomes                    of patients treated for chronic lymphocytic leukemia in British Columbia,                    Canada. Leuk Res. 2021; 103:                    106538.","DOI":"10.1016\/j.leukres.2021.106538"},{"key":"21","doi-asserted-by":"crossref","unstructured":"21 Lipsky                            A,                                Lamanna                            N. Managing                    toxicities of Bruton tyrosine kinase inhibitors. Hematology Am Soc Hematol Educ                    Program. 2020; 2020: 336-345.","DOI":"10.1182\/hematology.2020000118"},{"key":"22","doi-asserted-by":"crossref","unstructured":"22 Thompson                            MC,                                Roeker                            LE,                                Coombs                            CC                    <i>et al.<\/i> Addressing a New Challenge in Chronic Lymphocytic                    Leukemia: Outcomes of Therapies after Exposure to Both a Covalent Bruton\u2019s                    Tyrosine Kinase Inhibitor and Venetoclax. Blood. 2021; 138:                    2628.","DOI":"10.1182\/blood-2021-150751"},{"key":"23","doi-asserted-by":"crossref","unstructured":"23 Wang                            E,                                Mi                            X,                                Thompson                            MC                    <i>et al.<\/i> Mechanisms of Resistance to Noncovalent Bruton\u2019s                    Tyrosine Kinase Inhibitors. N Engl J Med. 2022; 386: 735-743.","DOI":"10.1056\/NEJMoa2114110"},{"key":"24","unstructured":"24 Acalabrutinib Receives Approval for                    Treatment-Na\u00efve Chronic Lymphocytic Leukemia in Japan. Available on                    https:\/\/www.cancernetwork.com\/view\/acalabrutinib-receives-approval-for-treatment-na-ve-chronic-lymphocytic-leukemia-in-japan.                    Accessed on 17 April 2023."},{"key":"25","unstructured":"25 Acalabrutinib Approved in Japan for                    Relapsed\/Refractory CLL. Available on                    https:\/\/www.onclive.com\/view\/acalabrutinib-approved-in-japan-for-relapsed-refractory-cll.                    Accessed on 17 April 2023."},{"key":"26","unstructured":"26 FDA U. TREANDA<sup>\u00ae<\/sup> (bendamustine                    hydrochloride) prescribing information. Vol 20222008."},{"key":"27","unstructured":"27 FDA U. Rituximab prescribing information.                    Vol 20222022."},{"key":"28","doi-asserted-by":"crossref","unstructured":"28 Mato                            AR,                                Shah                            NN,                                Jurczak                            W                    <i>et al.<\/i> Pirtobrutinib in relapsed or refractory B-cell                    malignancies (BRUIN): a phase 1\/2 study. Lancet. 2021; 397:                    892-901.","DOI":"10.1016\/S0140-6736(21)00224-5"},{"key":"29","doi-asserted-by":"crossref","unstructured":"29 Shah                            NN,                                Wang                            ML,                                Brown                            JR                    <i>et al.<\/i> Safety and Tolerability of Pirtobrutinib Monotherapy in                    Patients with B-Cell Malignancies Who Were Previously Intolerant to a Covalent                    BTK Inhibitor: Results from the Phase 1\/2 BRUIN Study. Blood. 2022; 140:                    4127-4132.","DOI":"10.1182\/blood-2022-159035"},{"key":"30","doi-asserted-by":"crossref","unstructured":"30 Woyach                            JA,                                Blachly                            JS,                                Rogers                            KA                    <i>et al.<\/i> Acalabrutinib plus Obinutuzumab in Treatment-Na\u00efve and                    Relapsed\/Refractory Chronic Lymphocytic Leukemia. Cancer Discov. 2020; 10:                    394-405.","DOI":"10.1158\/2159-8290.CD-19-1130"},{"key":"31","doi-asserted-by":"crossref","unstructured":"31 Woyach                            J,                                Huang                            Y,                                Rogers                            K                    <i>et al.<\/i> Resistance to Acalabrutinib in CLL Is Mediated Primarily                    By BTK Mutations. Blood. 2019; 134: 504.","DOI":"10.1182\/blood-2019-127674"},{"key":"32","doi-asserted-by":"crossref","unstructured":"32 Naeem                            A,                                Utro                            F,                                Wang                            Q                    <i>et al.<\/i> Pirtobrutinib targets BTK C481S in ibrutinib-resistant                    CLL but second-site BTK mutations lead to resistance. Blood Adv. 2023; 7:                    1929-1943.","DOI":"10.1182\/bloodadvances.2022008447"},{"key":"33","doi-asserted-by":"crossref","unstructured":"33 Jones                            JA,                                Mato                            AR,                                Wierda                            WG                    <i>et al.<\/i> Venetoclax for chronic lymphocytic leukaemia progressing                    after ibrutinib: an interim analysis of a multicentre, open-label, phase 2                    trial. Lancet Oncol. 2018; 19: 65-75.","DOI":"10.1016\/S1470-2045(17)30909-9"},{"key":"34","unstructured":"34 US FDA. TREANDA<sup>\u00ae<\/sup> (bendamustine                    hydrochloride) prescribing information 2008. Available on                    https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2008\/022303lbl.pdf.                    Accessed on 25 November 2022."},{"key":"35","unstructured":"35 US FDA. Rituximab prescribing information                    2022. Available on                    https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2010\/103705s5311lbl.pdf.                    Accessed on 25 November 2022."}],"container-title":["Journal of Clinical and Experimental Hematopathology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/jslrt\/63\/4\/63_23032\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,13]],"date-time":"2024-05-13T05:17:51Z","timestamp":1715577471000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/jslrt\/63\/4\/63_23032\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12,26]]},"references-count":35,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2023]]}},"URL":"https:\/\/doi.org\/10.3960\/jslrt.23032","relation":{},"ISSN":["1346-4280","1880-9952"],"issn-type":[{"value":"1346-4280","type":"print"},{"value":"1880-9952","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,12,26]]},"article-number":"23032"}}